Controlling Shareholder Robert Duggan Buys $13M in Open Market

summarizeSummary

Controlling shareholder Robert W. Duggan purchased over $13 million of Pulse Biosciences common stock through an ATM program, reinforcing his significant stake and demonstrating strong confidence.

check_boxKey Events

• Significant Insider Purchase

  Robert W. Duggan, the controlling shareholder, purchased 660,233 shares of common stock for approximately $13.01 million on May 11, 2026.

• Acquisition via ATM Program

  The shares were acquired through the company's existing at-the-market (ATM) equity offering program, which was recently approved for affiliate purchases.

• Increased Controlling Stake

  Duggan's beneficial ownership now stands at 49,706,423 shares, representing 71.9% of the company's outstanding common stock.

• Strong Conviction Signal

  This substantial open-market investment by the primary shareholder indicates strong confidence in Pulse Biosciences' prospects.

auto_awesomeAnalysis

Robert W. Duggan, the controlling shareholder of Pulse Biosciences, made a substantial open-market purchase of over $13 million worth of common stock. This significant investment, executed through the company's at-the-market (ATM) program, reinforces his already dominant 71.9% stake and signals strong conviction in the company's future, especially following a series of positive clinical and regulatory developments.